Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: J Immunol. 2020 Jan 17;204(5):1386–1394. doi: 10.4049/jimmunol.1900742

Figure 1. CMP-001 VLP-induced cytokine production from human PBMCs is dependent on anti-Qβ and pDCs.

Figure 1.

A, Ig anti-Qβ levels detected in clinical trial human patient serum before (naïve) and after (immune) treatment with CMP-001 (data is representative of 7 replicate experiments; n=20 patients measured in total). IFNα levels produced by: (B) human PBMCs cultured with or without CMP-001 and immune serum, (C) human PBMCs cultured with or without CMP-001 or methylated CMP-001 (metCMP-001) and recombinant anti-Qβ, (D) human PBMCs, pDC-depleted PBMCs or purified pDCs cultured with or without CMP-001, recombinant anti-Qβ, and immune serum, or (E) human PBMCs cultured with anti-CD32 or control antibody prior to CMP-001 and anti-Qβ (data is representative of 2 replicate experiments; n=2–3 replicates per experimental group). F, Confocal microscopy images from purified pDCs incubated with fluorescently labeled CMP-001 −/+ anti-Qβ (green=BDCA-2, blue=DAPI, red=CMP-001; data is representative of 3 replicate experiments; n=2–3 replicates per experimental group). G, Cytokine levels produced by human PBMCs cultured with or without CMP-001 and immune serum (data is representative of 3 replicate experiments; n=2–3 replicates per experimental group). Data were analyzed using either a one-way ANOVA with Tukey’s multiple comparisons test (C-D and G) or a two-way ANOVA with Sidak’s multiple comparisons test (E-F); *P<0.05; **P<0.01; ****P<0.0001.